Evolving Techniques and Indications of Descemet Membrane Endothelial Keratoplasty

Özlem Evren Kemer*, Emine Esra Karaca*, Silke Oellerich**, Gerrit Melles**

*University of Health Sciences Turkey, Ankara City Hospital, Ankara, Turkey  
**Netherlands Institute For Innovative Ocular Surgery (NIIOS), Rotterdam, The Netherlands

Abstract

Endothelial keratoplasty (EK) offers great advantages for the treatment of corneal endothelial dysfunction. It offers faster, more predictable, stable visual recovery and low rejection rates while the surgery itself is less invasive. Descemet membrane endothelial keratoplasty (DMEK) is currently the gold standard for the treatment of Fuchs endothelial dystrophy, bullous keratopathy, and corneal edema after cataract surgery. Its favorable long-term outcomes are increasingly reported by large study groups. This review summarizes the current literature on new DMEK techniques, including size and shape modifications, new graft delivery techniques, and surgical pearls for challenging cases like eyes with glaucoma, glaucoma tubes, and failed penetrating keratoplasties.

Keywords: Corneal transplantation, DMEK, hemi-DMEK, quarter-DMEK, DMEK in complicated cases

Introduction

Endothelial keratoplasty (EK) offers great advantages for the treatment of patients with endothelial dysfunction. It can be performed for Fuchs endothelial dystrophy, pseudophakic or aphakic bullous keratopathy, posterior polymorphous dystrophy, iridocorneal endothelial syndrome, or failed penetrating keratoplasty (PK). It provides more rapid visual recovery, lower rejection rates, better refractive outcomes, and greater structural integrity than traditional PK.1,2,3,4 Moreover, it provides a closed system that prevents PK’s most dreadful complication: intraoperative suprachoroidal hemorrhage.5,6

Modern EK techniques include mainly Descemet stripping automated EK (DSAEK), Descemet membrane EK (DMEK), and pre-Descemet EK (PDEK).7 In 2006, Melles1 first introduced DMEK that selectively replaces the Descemet membrane (DM) and endothelium, resulting in an anatomically accurate procedure. DMEK poses some technical challenges, such as the need for careful graft preparation and meticulous graft orientation techniques, which result in a steep learning curve.5 Despite this, DMEK has gained popularity in the last decade, and various modifications have been introduced that are gradually improving the surgical technique or donor preparation in challenging situations.8

As DMEK surgery became more popular, more information on its mid- and long-term results also became available. Recently, Birbal et al.10 reported outcomes for a cohort of 500 DMEK eyes with a 5-year graft survival probability of 0.90 and 82% of eyes achieving a best-corrected visual acuity (BCVA) of 20/25. The endothelial loss was 37% in the first 6 months, 40% at 1 year, and 55% at 5 years. Allograft rejection rates were as low as 1.7-2.8% compared to 5% in DSAEK and 14% in PK.10 Woo et al.11 compared DMEK survival at 5 years (97.4%) with DSAEK (76.4%) and PK (54.6%). Even after 10 years, pioneering DMEK surgery cases maintained excellent visual acuities with low rejection rates, further supporting DMEK as the gold standard treatment for corneal endothelial diseases.11

Address for Correspondence: Özlem Evren Kemer, University of Health Sciences Turkey, Ankara City Hospital, Ankara, Turkey  
E-mail: ozlemvidya@gmail.com ORCID-ID: orcid.org/0000-0001-9480-8470  
Received: 31.12.2020 Accepted: 18.05.2021

Cite this article as: Kemer ÖE, Karaca EE, Oellerich S, Melles G. Evolving Techniques and Indications of Descemet Membrane Endothelial Keratoplasty.  
Turk J Ophthalmol 2021;51:381-392

©Copyright 2021 by Turkish Ophthalmological Association  
Turkish Journal of Ophthalmology, published by Galenos Publishing House.
In this review, we will discuss new perspectives, various indications of DMEK, and elucidate the surgical steps of DMEK in challenging cases in light of recent scientific publications.

**New Techniques of Graft Preparation and Insertion**

**Hemi-DMEK**

DMEK provides fast visual recovery in the treatment of endothelial dysfunction. However, a donor corneal tissue with good endothelial cell density is required for the procedure. Due to the worldwide shortage of suitable donor tissue for EK procedures, the idea of splitting the donor tissue into two or more grafts while keeping similar surgical success evolved (Table 1). Lam et al. were the first to describe a half-moon (semicircular) hemi-DMEK technique. In regular DMEK surgery, an 8.0 mm graft is sufficient to achieve corneal clarity. A hemi-DMEK graft utilizes a larger diameter graft, like 11-12 mm, and divides it into two. This way, the surface area of a hemi-DMEK graft and the number of transplanted corneal endothelial cells are comparable to regular DMEK. Although it is advantageous in terms of tissue efficiency, it presents some challenges in preparation and intraocular graft positioning. In this technique, after mounting the corneoscleral buttons endothelial side up, uveal remnants are removed and the DM is loosened with a knife in the central direction. Then the buttons are separated into two halves and the DM is removed from the posterior stroma as two half-moon shaped grafts without any trephination. Except for the diameter of the graft, a routine DMEK surgery is performed. While orienting the graft, the widest diameter is aligned to the longest horizontal meridian so that the largest part of the graft covered the pupillary area (Figure 1a).

The healing period also has unique properties. Some denuded corneal stroma is left after surgery because of the mismatch between the descemetorhexis area and the graft. Clinically, the postoperative corneal edema resolves in 12 months and the denuded area is covered with endothelial cells. It is still not clear whether the posterior denuded stroma is covered via the migration of donor or recipient endothelial cells. Müller et al. showed that endothelial cell density was decreased by 59% in the first year and stayed stable for 3 years. Visual acuity was improved, and no complications were seen intraoperatively or postoperatively. The corneas were clear and presented with stable pachymetry in 1- and 3-year clinical follow-ups. Hemi-DMEK led to similar outcomes to conventional DMEK; therefore, it may be a promising technique due to its potential to double the number of endothelial transplants from the same donor cornea.

**Quarter-DMEK**

The idea of stromal repopulation by host endothelial cells after a complete Descemet graft detachment or “descemetorhexis only” (descemetorhexis without EK) surgery helped to design a technique called “quarter-DMEK.” Since host cellular migration is slow in patients with descemetorhexis only, quarter-DMEK could be described as a hybrid technique that combines the advantage of DMEK (achieving rapid corneal clearance) with DM endothelial transfer (DMET) (stimulates peripheral host endothelium). One donor cornea can yield four endothelial grafts by this procedure. Zygoura et al. evaluated the outcome of quarter-DMEK applied in 12 patients with central Fuchs endothelial dystrophy. As in hemi-DMEK, the corneoscleral buttons were mounted endothelial side up, uveal remnants were removed, and the DM was loosened with a knife in a central direction. However, the buttons were then separated into four equal parts and the DM was removed from the posterior stroma as four equal grafts. All DM grafts were rolled with the endothelium on the outside and kept in an organ culture medium until transplantation. After a 7-8 mm descemetorhexis under air, routine DMEK surgery was performed with the graft oriented centrally (Figure 1b). They followed the patients for 6 months and reported that all of the eyes reached a BCVA of ≥20/40 (≥0.5) and 11 of 12 eyes (92%) achieved a BCVA of ≥20/25 (≥0.8). The rebubbling rate was 33% within the first 2 months. However, they showed a quick drop in endothelial cell density in the first month. Extensive endothelial cell migration and error of measurement at the graft edges could be the reason for this drop. The authors also described a higher tendency for corneal clearance along the cut edges of the grafts compared to the “limbal” rounded edge, which may reflect different cell migration patterns in different graft areas. It was hypothesized

| Type of DMEK | Difference from standard DMEK | Advantage | Disadvantage | Defined by |
|--------------|-------------------------------|-----------|--------------|------------|
| Hemi-DMEK    | Uses half of a larger sized graft | 2 grafts from one donor | Challenges with graft preparation and positioning | Melles et al. |
| Quarter-DMEK | Uses a quarter of a larger sized graft | 4 grafts from one donor | Challenges with graft preparation and positioning | Melles et al. |
| ¾-DMEK       | Uses three quarters of a larger sized graft | Can be used in the presence of tubes in the anterior chamber | Challenges with graft preparation and positioning | Melles et al. |
| E-DMEK (EndoGlide) | The graft is prepared the same way but folded “endothelium-in” | Easier unfolding, especially in challenging cases | Requires special cartridge for delivery | Mehta et al. |
| H-DMEK (Hybrid) | Similar to E-DMEK, the graft is prepared with a thin stroma that acts like a carrier | Easier unfolding, especially in challenging cases | Requires 4.5 mm corneal incision, challenging graft preparation | Woo et al. |

DMEK: Descemet membrane endothelial keratoplasty
that the repopulating cells at the rounded graft edges were probably host endothelial cells.

Birbal et al.\textsuperscript{22} reported the clinical outcomes of 19 patients with central Fuchs endothelial dystrophy. These patients showed good visual outcomes, and the visual acuities were stable for 2 years postoperatively. Eight of 19 eyes (42\%) required rebubbling due to significant graft detachment. Good outcomes of quarter-DMEK were also reported by Oganesian et al.\textsuperscript{23} Quarter-DMEK may be comparable to conventional DMEK in terms of visual acuity outcomes and increase the availability of endothelial grafts.\textsuperscript{22}

**E-DMEK**

Despite the many advantages of DMEK, technical difficulties in graft insertion and unfolding led to a new surgical technique called EndoGlide-DMEK (E-DMEK).\textsuperscript{24,25} This technique features several differences in graft preparation and insertion. In this technique, the graft is prepared in a standard manner,

Figure 1a. Slit-lamp images, pachymetry maps, and specular microscopy images before and after hemi-DMEK (Descemet membrane endothelial keratoplasty). Images obtained preoperatively and at 6 months postoperatively are shown. The dashed yellow lines show the position of the hemi-DMEK grafts.

Figure 1b. Slit-lamp images, pachymetry maps, and specular microscopy images before and after quarter-DMEK (Descemet membrane endothelial keratoplasty). Images obtained preoperatively and at 6 months postoperatively are shown.
but it is tri-folded in an endothelium-in fashion using a forceps rather than the natural endothelium-out orientation. It is then loaded in a cartridge and inserted through a corneal incision (Figure 2a-f). Rather than being injected, it is pulled into the anterior chamber (AC) by grasping with a forceps from the opposing corneal incision. Once an endothelium-in graft enters the AC, it unfolds easily with fewer maneuvers. Keeping the AC shallow is critical for this technique as the graft would scroll back to the endothelium-out orientation in a deep AC. E-DMEK is especially designed for challenging cases like those with abnormal anterior segment anatomy, gross peripheral anterior synchiae, drainage devices, and filtering blebs. It is similar to DSAEK graft insertion, so it may be technically easier for surgeons who are accustomed to DSAEK surgery during the transition to DMEK surgery.

Tan et al. showed both ex vivo and clinical results of E-DMEK. In an ex vivo study, DMEK grafts were stained with calcin acetoxyethyl, tri-folded in the endothelium-in fashion, and placed into the EndoGlide. Then they were pulled through and unfolded in imaging dishes simulating a real surgery. Mean endothelial cell loss was 15.2% ± 5.4% in 9 human corneas. In a clinical series, endothelial cell loss was 33.6% (range 7.5%-80.4%) among 69 eyes with at least 6 months follow-up. Rebubbling and primary graft failure rates were 11.6% and 1.5%, respectively. In conclusion, they suggested E-DMEK was a safe and promising alternative to standard DMEK due to its good clinical outcomes.

**H-DMEK**

Woo et al. developed a new technique called hybrid DMEK (H-DMEK). They used the DSAEK pull-through donor inserter and donor stroma as a carrier while performing DMEK. In this technique, pre-cut DSAEK donor tissue from the eye bank that was approximately 150 µm in thickness was utilized. During graft preparation, a Tan DMEK stripper was used for lamellar dissection of the DM from the underlying stroma, but the DM was not completely removed from the stroma. The DMEK graft and stromal carrier were loaded into the EndoGlide inserter device in a double-coil endothelium-in configuration. The glide was inverted so that the graft would be placed in an endothelium-down fashion. It was inserted through a scleral tunnel into the AC. The DMEK graft edge was pulled with forceps from the nasal paracentesis incision into the AC, completely detaching from the donor stroma and leaving the stroma behind. H-DMEK is similar to E-DMEK as the graft is placed in an endothelium-in fashion. The difference is the presence of a thin stromal component during graft preparation. The thin stroma acts like a carrier of the DMEK graft. This difference makes it easier to handle and fold the graft while placing it in the basin. The need for a 4.5 mm incision to deliver the graft into the AC and more complicated steps in graft preparation are potential disadvantages.

Eighty-five eyes of 79 patients with Fuchs endothelial dystrophy or bullous keratopathy were involved in the clinical study. Of the eyes without pre-existing ocular pathology, 44.7% and 57.1% showed a BCVA of 20/25 or better at 6 and 12 months postoperatively, respectively. Endothelial cell loss was 32.2% at 6 months. The authors suggested that this technique might be useful in complicated cases.

**DMEK in Vitrectomized Eyes**

Although DMEK surgery is gaining popularity for endothelial dysfunction, vitrectomized eyes undergoing DMEK still pose a challenge. Due to the lack of posterior support of the vitreous, the AC is mostly deep, and graft unfolding can be difficult. Excessive manipulation of the donor tissue while
unfolding may lead to graft failure. Additionally, the injected air bubble used to tamponade the graft toward the stroma may be less effective due to a fluctuating iris-lens diaphragm. As injected air tends to move posteriorly, recurrent globe collapse is a significant problem. Furthermore, the DMEK graft may dislocate into the vitreous cavity. However, the challenges should not discourage surgeons from proceeding with DMEK, as some surgical modifications have been described for these eyes to improve the outcome. The main philosophy for DMEK graft unfolding relies on a shallow and stable AC. Moreover, donor age is important in these eyes. Age-dependent decrease in elastin levels, change in collagen composition, and increase in nonenzymatic glycosylation cause an increase in DM rigidity. Therefore, older donor grafts unfold more easily and are more appropriate for these eyes.

Yoeruek et al. tried a new maneuver for unfolding the graft in high myopic vitrectomized eyes. After inserting the DMEK graft, they performed equatorial digital indentation and corneal tapping for unfolding. During this maneuver, they avoided using air injection above or below the graft. After centration and unfolding, air was injected below the graft for apposition against the posterior stroma. The AC was filled totally with air. They first published their results in a case series with 6 Fuchs endothelial dystrophy and 4 bullous keratopathy eyes. Three of 10 eyes had graft detachment and required rebubbling, but they showed no graft failure during the follow-up period. Although this technique worked quite well for Fuchs endothelial dystrophy and bullous keratopathy eyes, they had difficulties in vitrectomized eyes. Their retrospective clinical study of 20 vitrectomized eyes that underwent DMEK surgery showed that 13 of them had significant intraoperative complications. Intraoperative corrective measures were quite difficult in a few cases, and iatrogenic intraocular damage was encountered in some of them. Unfolding the graft was quite difficult. Eleven eyes had graft dislocation and two had iatrogenic primary graft failure.

Sorkin et al. performed DMEK in vitrectomized eyes using posterior pars plana infusion. In this technique, after DMEK grafts were prepared with an “F” marking, a 23-gauge trocar was inserted at the inferotemporal quadrant, 3.0 mm from the limbus. Infusion pressure was set between 5-26 mmHg depending on the stability of the AC. After descemetorhexis, a glass pipette or intraocular lens (IOL) injector was used to deliver the graft. The pars plana infusion was turned on and off to maintain optimal eye pressure and a shallow AC. This facilitated graft unfolding and positioning. Yoeruek’s tapping technique (corneal tapping with external digital pressure application) was used during the unfolding. After the graft was unrolled and positioned, the posterior infusion was turned off and the AC was filled with air. The trocar was extracted from the eye, and corneal incisions and any leaky sclerotomy sites were sutured. The authors performed this technique on 12 vitrectomized eyes and had one graft detachment, which required rebubbling. No graft failure was experienced during the follow-up period. Another study by the same group evaluated the long-term outcomes up to 2 years. They reported 5 of 15 eyes had retinal complications, including retinal detachment, retinoschisis, and cystoid macular edema. Although using posterior pars plana infusion could potentially reduce intraoperative and postoperative complications in vitrectomized eyes, the authors also cautioned that using an infusion could increase retinal complication risks.

Some of the vitrectomized eyes may also have sutured IOLs. In these patients, several maneuvers may be required to unfold the DMEK graft. These eyes are monocameral, and this situation may lead the graft to migrate to the posterior cavity. Additionally, the globe is prone to collapse, which makes graft unfolding quite difficult. Hayashi et al. described a modified technique called the “double-bubble technique for DMEK for vitrectomized eyes.” It was the modification of a small air bubble-assisted unrolling maneuver (Dapena maneuver). In this technique, after inserting the DMEK graft, one small air bubble was placed over the graft for unfolding, and the other large bubble was injected beneath the graft for fixation. If peripheral edges were not attached, they applied bubble-bumping maneuvers to unfold the edges. Despite the unfolding time being relatively long, all of the surgeries were successful. In the follow-up period, one eye required rebubbling.

Although using 23-gauge infusion helps to stabilize the globe, unfolding the donor graft is still a problem due to its strong recurling tendency. The equatorial digital indentation and corneal tapping techniques are helpful mainly in partially vitrectomized eyes. Eyes with completely removed vitreous still pose several challenges. In the normal eye, the vitreous applies a counter-pressure and limits the motion of the iris-lens diaphragm. As iris-lens diaphragm stability is necessary for DMEK surgery, Yoeruek et al. described a new technique using a temporary diaphragm for easier graft unfolding. Following descemetorhexis, a hydrophilic methacrylate sheet measuring 12.8 mm with holes in the periphery was implanted into the AC to create a double AC. A DMEK graft was injected into the AC over the hydrophilic methacrylate sheet and unfolded. Under continuous air injection through a 30-gauge cannula, the hydrophilic methacrylate sheet was removed. Sulfur hexafluoride gas at a concentration of 20% was preferred for longer tamponade. Seven eyes of 7 patients who underwent DMEK by this method showed no complications intraoperatively or postoperatively. Karadağ et al. tried using the posterior corneal stroma instead of a hydrophilic methacrylate sheet for the same purpose.

Saad et al. described the C-press technique in 11 eyes of 11 patients who underwent DMEK. They reported that their experience with pars plana infusion and double-bubble technique in vitrectomized eyes were not reproducible in all cases; therefore, another new approach was required. Following descemetorhexis and DMEK graft insertion into the AC, correct graft orientation was ascertained by intraoperative optic coherence tomography. A cannula was then inserted inside the graft (Descemet side) and moved right and left to open it by irrigating with balanced salt solution. At the same time, a second cannula held in the other hand pressed externally on the central cornea. Shallowing the
AC with this pressure helped the graft to remain open. Then the first cannula was removed and 20% SF6 gas was injected. No intraoperative complications were experienced; however, 2 cases needed rebubbling for partial graft detachment. Lower unfolding time and complication rates were advantages of this technique.

These evolving techniques show that we do not have a standard, straightforward approach suitable for all vitrectomized eyes. It is advisable to get familiar with different methods so they can be readily applied when needed.

**DMEK After Failed PK**

After PK, secondary graft failure and late endothelial decompensation are likely to increase with the aging graft. In the past, the only options were repeating PK and implanting keratoprosthesis for managing failed PK. \(^{41,42}\) Recently, EK has allowed restoration of endothelial function in failed PK grafts and decreased the need for a full-thickness graft. This reduces the risk of rejection and refractive changes and avoids the complications associated with “open-sky” surgery. \(^{43-46}\) DMEK has acceptable outcomes in patients with failed PK. However, recent literature shows that it is associated with a high postoperative graft detachment rate, ranging between 26-100%. \(^{47,48}\) Nevertheless, since the DMEK graft is thin and flexible, a better apposition could be achieved with DMEK-grafts compared to the “stiffer” DSAEK graft. Also, DMEK grafts should better fit the irregular posterior surface and PK wound and could cover more surface area. \(^{49}\) Lavy et al. \(^{50}\) evaluated the clinical outcomes of 11 DMEK surgeries for secondary PK failure. They described some surgical modifications and specific manipulations while performing DMEK in these patients. A corneal incision 3.0 mm wide was made in the host peripheral corneal rim without penetrating PK graft to avoid potential host-graft wound dehiscence. Descemetorhexis was started in the central area of the PK graft and was enlarged in a curvilinear pattern, like capsulorhexis, under air using a reverse Sinskey hook. The remaining part of the surgery was routine DMEK surgery (Figure 3a). The authors mentioned that circular scarring at the PK graft-host junction sometimes blurred the edges of the DMEK graft, and visualization was not always possible. Four of 11 eyes required rebubbling, and 7 of 11 eyes were clear at their last visit. Additionally, they showed that graft attachment could be achieved in eyes with failed PK grafts through interface scarring that was detected in histopathological specimens after the patient’s death. The specimens with areas of detachment clinically showed a layer of newly formed fibrotic tissue extending from the PK wound area to the central and peripheral graft areas. Although the scar tissue formation may be a normal wound-healing process, the fibrotic response was more aggressive than in primary DMEK eyes, resulting in diffuse interface haze. Overall, three important points were emphasized: there may be delayed DMEK graft detachment, which may need rebubbling. Second, oversized DMEK grafts were more prone to detach. Third, pressurizing the eye adequately at the end of the surgery is critical. Otherwise, hypotony could lead to detachment of the graft.

Pasari et al. \(^{51}\) reviewed 93 DMEK procedures performed in 84 eyes of 77 patients with failed PK. Stripping was done within the edge of the PK wound and avoiding the graft-host junction. Failed PK graft diameter, recipient horizontal corneal white-to-white diameter, and AC depth were evaluated intraoperatively to select the donor graft diameter. The graft was oversized, same-sized, or undersized. The 4-year graft survival rate of these patients was found to be 76%. They also showed that previous glaucoma surgery was the only risk factor for graft failure. Additionally, rebubbling rates changed depending on graft size. The rates were 53% when the DMEK graft diameter was oversized, 27% when same-sized, and 33% when undersized.

DMEK surgery under a failed PK may be challenging due to DM tags or stromal fibers caused by traumatic DM stripping. The maneuvers may affect DM graft adhesion and increase graft detachment risk. Some authors claimed DMEK could be done without removing the DM of the failed graft. \(^{52}\) Alio Del Barrio et al. \(^{53}\) performed non-Descemet stripping DMEK (NS-DMEK) and recommended either matched or undersized 0.25-0.50 mm grafts to avoid the PK donor-host junction. They also used SF6 tamponade to decrease the risk of graft detachment. All eight patients in the study achieved full PK transparency within two weeks. One patient required rebubbling, and one required PK re-suturing due to host-donor junction dehiscence. With this technique, DMEK surgery in failed PK patients was simplified and intraoperative complications were avoided.

Recently, femtosecond laser-assisted descemetorhexis has been recommended in patients with failed PK who do not have stromal scarring and have normal AC anatomy. \(^{27,54}\) Sorkin et al. \(^{55}\) performed femtosecond laser-assisted DMEK for failed PK in 8 patients. In this technique, descemetorhexis was planned 0.25 mm smaller than the PK graft to prevent graft dehiscence and incomplete incision. \(^{56}\) The Intralase iFS femtosecond laser platform enabled a precisely located deep vertical ring cut. Then, the DM was removed from the stroma using a reverse Sinskey hook. Deep dissection into the stroma was avoided. The remainder of the surgery was similar to standard DMEK. In this study, no cases required re-bubbling, and only one eye (12.5%) had a small graft detachment, which did not affect corneal clarity and vision. The same group compared manual (M) and femtosecond laser-assisted (F) DMEK for failed PK. \(^{56}\) They showed that F-DMEK was effective and safe in failed PK patients, and rebubbling rates were lower than for M-DMEK. Primary failure was lower in F-DMEK; however, there was no significant difference compared to M-DMEK. Visual outcomes and postoperative cell densities were similar between the groups. Although the precise reason for the reduced detachment rate is unclear, they suggested that F-DMEK could lead to complete removal of the host’s DM with less remnant Descemet tags and islands. In addition, the host DM peripheral to the descemetorhexis remains undamaged. While...
F-DMEK looks promising, the data is currently limited to 10 patients.

**DMEK in Eyes with Prior Glaucoma Surgery**

Glaucoma predisposes a high risk for graft failure in either PK, DSAEK, or DMEK due to both surgical and immunological challenges. Technically it is more challenging to position a DMEK graft in the setting of previous glaucoma surgery because these eyes usually have comorbidities like synechia, aphakia, tubes, or pupillary abnormalities that need several surgeries. It is harder to keep the air in the AC. These technical difficulties also result in prolonged surgical time and extra maneuvers, resulting in increased endothelial loss which leads to secondary graft failure. Lysis of anterior synechia and trimming the tube are some of the additional techniques used in these complex eyes. Immunologically, eyes also lose their immune privilege after glaucoma surgery because it alters the aqueous composition.

Arevena et al. reported early outcomes of DMEK in eyes with previous trabeculectomy or a drainage device. Surprisingly, they did not encounter secondary failures in the first postoperative year. After Birbal et al. described the decrease of graft survival from 89% at 1 year to 67% at 2 years, similar studies on this subject emerged. Pasari et al. showed graft survival probability gradually decreased from 78% at 1 year to 39% at 3 years. Sorkin et al. investigated graft survival at 4 years based on previous studies showing a possible downward trend of graft survival over time. They found a survival drop over the third and fourth postoperative years, with cumulative 2-, 3-, and 4-year DMEK survival probability rates of 60%, 43%, and 27%, respectively. Although eyes without glaucoma drainage devices (GDD) have better graft survival than eyes with GDD, they are more prone to graft failure than the control group, suggesting that glaucoma itself affects the long-term survival of DMEK grafts. Beyond graft failure, they found a significantly high rejection rate compared to the control group (19.6% vs. 2.3%, p=0.01). The baseline high inflammatory status of eyes with previous glaucoma surgery due to disruption of the blood-aqueous barrier may be one of the reasons leading to this difference.

---

**Figure 3a.** Slit-lamp images before and after Descemet membrane endothelial keratoplasty, postoperative pachymetry map and specular microscopy image of an eye with a failed penetrating keratoplasty graft

**Figure 3b.** Slit-lamp images before and after Descemet membrane endothelial keratoplasty, postoperative pachymetry map and specular microscopy image of an eye with a glaucoma drainage device superotemporally (orange arrows)
Endothelial cell loss is another important consideration in patients with prior glaucoma surgery. In addition to rejection-related cell loss, alterations of the aqueous environment may also contribute to ongoing cell loss in these eyes. Aravena et al. showed that endothelial cell loss was higher in the surgery group (44.6% ± 17.8%) than in the medically treated group (29.9% ± 12.0%) and the control group (32.7% ± 11.3%, p = 0.001). Some potential factors such as inflammation, oxidative stress, and increased plasma proteins are included in endothelial apoptosis after glaucoma surgery. Sorkin et al. touched on another point about the trend of endothelial cell loss. Endothelial cell loss was highest in the first 6 postoperative months (about 44%), which was not different from other DMEK cases. After that, endothelial cell loss was higher in patients with glaucoma, about 12%-22%. The significant difference in endothelial cell loss continued throughout follow-up.

Apart from glaucoma surgery itself, the tube’s position is quite important for graft survival and endothelial cell loss. Intermittent tube-uveal contact may result in corneal endothelial damage. Therefore, some technical modifications are recommended for GDD patients. The area of the GDD should be avoided while creating a 3.0 mm clear corneal incision at 12 o’clock position, and the superior conjunctiva was avoided for future glaucoma surgery. During graft insertion, contact between graft and tube should be prevented. The tube could be trimmed for better graft positioning. Additionally, Descemet graft unfolding should be performed over the tube, not over the iris (Figure 3b). This could be difficult in some cases; therefore, a modified “three-quarter DMEK technique” (3/4-DMEK) was designed and evaluated in three patients by Oganesyan et al. All of the patients had previous Ahmed valve implantation and were pseudophakic. During graft preparation, the DM was stripped from the posterior stroma and put over a soft contact lens. Two perpendicular cuts with a keratome (MANI Inc, Tokyo, Japan) helped separate a quarter of the graft and create a 3/4-DMEK graft. In the host cornea, an 11-12 mm diameter descemetorhexis was performed, sparing the area under the GDD. While unfolding the graft, the missing 1/4-graft area was adjusted to the region of the tube, and the 3/4-DMEK graft was positioned centrally. The AC was filled 100% with air. All of the DMEK surgeries were uneventful, and grafts were stable up to postoperative 24 months. Endothelial cell loss was similar to previous studies (range 49%-64%) within the first year, as with conventional DMEK. The absence of the graft under the tube prevented direct tube contact with the graft and may be beneficial for the graft's postoperative survival. Possible cell migration from the graft to the recipient stroma was minimized by leaving the host DM intact under the tube. Despite the promising results of this technique, they suggested the need for long-term follow-ups and larger case series.

The mechanical effect of the GDD, active filtration of air through filtering ostium or tube, and posterior escape of air through a large iridectomy are some of the factors blamed for high graft detachment and rebubbling rates (22.0%-23.5%). Contrary to this popular belief, Sorkin et al. did not find increased detachment and rebubble rates in these patients. They also stated that preoperative visual potential estimation of glaucomatous eyes was a challenge due to unknown adequate IOP control and prolonged standing corneal edema. Despite this challenge, 85% of patients had improved visual acuity, and none had a primary failure.

Although DMEK in patients with previous glaucoma surgery seems to have challenges, it should be performed by considering some critical steps and modifications. Graft survival is reduced not only in DMEK but in all other keratoplasty techniques. Therefore, these patients should be given the opportunity to undergo DMEK despite the risk of future re-grafting.

**DMEK and Cataract Surgery**

Although triple DMEK (simultaneous DMEK, cataract surgery, and IOL implantation) is often preferred in phakic patients, this procedure may lead to a refractive shift that is difficult to predict. Some recent studies have shown that a small hyperopic shift could be observed after DMEK. Hence during IOL selection, these studies suggested a -0.50 to -1.0 D refractive target to provide emmetropia or slight myopia after DMEK. However, some individual cases showed large hyperopic and myopic shifts, particularly in advanced Fuchs endothelial dystrophy cases due to anterior curvature changes. Apart from accurate IOL selection, endothelial cell density loss and DMEK graft detachment rate are other areas of concern in these cases.

In recent studies, several approaches have been performed during triple DMEK. Laser et al. targeted -0.75 D refractive power for IOL selection. They did not find any adverse effect on endothelial cell function or graft adhesion due to the triple procedure. Schoenberg et al. targeted a -0.50 D shift from IOL calculation due to +0.50 D hyperopic shift expectation after DMEK. The spherical equivalent median value was 0.0 D (range -0.25 to 0.25) postoperatively, and no astigmatic change was seen.

The average endothelial cell loss after 6 months was 26% to 40% in recent studies. The difference was not significant between pseudophakic and triple DMEK eyes. Better visual outcomes were seen in triple DMEK eyes. Although visual outcomes are promising, overhydration of the cornea and viscoelastic use during cataract surgery may interfere with graft attachment in triple DMEK. Eliminating the use of viscoelastic during graft insertion is quite important. Another critical point is that the second eye’s refractive shift may follow that of the first eye. Therefore, the first eye could be a reference point for the second eye’s future surgery.

The need for toric IOLs to neutralize corneal astigmatism could be a major concern in a triple procedure. Yokogawa et al. evaluated 15 eyes of 10 patients with cataract extraction, toric IOL placement, and DMEK surgery for Fuchs corneal dystrophy. Keratoscopy measurements were obtained from Scheimpflug corneal imaging, and an online toric calculator was used to determine the cylinder power of the toric IOLs. The spherical
target varied between -0.50 and -1.00 D due to the mild mean hyperopic shift seen with DMEK surgery. Postoperatively, 61.5% of eyes gained uncorrected distance visual acuity better than 20/40 and mean best spectacle-corrected distance visual acuity (logMAR) increased from 0.21 ± 0.15 to 0.08 ± 0.12 (p < 0.01). The refractive astigmatism was also significantly decreased from 2.23 ± 1.10 D (range 0.75–4.25 D) to 0.87 ± 0.75 D (range 0.00–3.00 D) postoperatively (p < 0.01). In one eye, no improvement was observed due to rotational misalignment by 43 degrees. The prediction error of astigmatism at the corneal plane was 0.77 ± 0.54 D (range 0.10–1.77 D). Four eyes with preoperative with-the-rule corneal astigmatism had postoperative against-the-rule refractive astigmatism. The authors emphasized the importance of rechecking the IOL alignment after DMEK graft placement to avoid clockwise rotation of the IOL.

In the absence of cataract, phacoemulsification may be delayed as a future option after DMEK. However, if phacoemulsification after DMEK is required, its potential impact on graft function should be taken into account. Since DMEK grafts tend to adhere stronger to the recipient posterior stroma than “virgin” DM, manipulations during cataract surgery may not create a potential risk for DMEK graft dislocation. Musa et al. reviewed phacoemulsification outcomes after DMEK and did not show any graft dislocation or detachment in those eyes. The refractive outcome was mostly within ± 0.50 D. However, donor endothelial cell density decreased significantly in eyes with previous DMEK. This study included high-risk eyes (e.g., multiple intraocular surgeries, advanced glaucoma). It was mentioned that DMEK graft endothelium resistance to trauma may not be as good as “virgin” endothelium.

A hyperopic shift due to DMEK is an expected result. Some specific adjustments may be required in the triple procedure. However, cataract surgery after DMEK is more predictable. Therefore, no particular nomograms are obligatory in this situation.

DMEK in Complex Anterior Segment Changes

Other than the standard indication of Fuchs endothelial dystrophy, DMEK can serve as a routine procedure in endothelial decomposition even in complex preoperative situations such as the presence of anterior synechia of the iris, large iris defects, iridocorneal-endothelial (ICE) syndrome, aphakia, subluxated posterior chamber IOL, AC IOL, phakic IOL, and acute corneal hydrops. The main objective in these situations is to reconstruct the iris and iris-lens diaphragm intraoperatively or preoperatively while treating the patients with DMEK. The graft size should be selected according to available space, e.g., eyes with anterior synechia may require a smaller graft diameter.

Weller et al. presented 24 complex eyes with endothelial decompensation. They performed DMEK in eyes with ICE syndrome, aphakia, subluxated posterior chamber (PC) IOL, and AC IOL. The eyes with ICE syndrome (3 eyes) had anterior synechia that interfered with the opening of the chamber angle, corectopia, and a shallow AC. Synechiolysis was required in two eyes with DMEK, and rebubbling was performed in two eyes. However, no graft failure developed in follow-up visits. In eyes with aphakia, stabilizing the iris-lens diaphragm by implanting a scleral sutured PC IOL was performed as the initial step. In eyes with IOL subluxation or AC IOLs, IOL explantation and implantation of a scleral sutured PC IOL or scleral suture-fixation of the existing IOL were applied. Further surgical procedures such as pupilloplasty or anterior vitrectomy were performed if necessary. DMEK was performed after a mean of 5 ± 4 months. Four eyes required rebubbling but no graft failure was observed during postoperative examinations. The authors emphasized the importance of graft diameter in ICE syndrome depending on the extent of the synechia. Free retrocorneal surface is significant in the determination of graft diameter. Additionally, the authors suggested a two-step procedure for eyes with IOL problems to prevent graft dislocation in a destabilized AC.

In another study, eight eyes with either ICE (4 eyes) or posterior polymorphous corneal dystrophy (4 eyes) underwent DMEK. Three of the eyes had goniounechiolysis and one eye had iridoplasty with DMEK. BCVA increased in all of the eyes. No graft failure or graft rejection was observed during follow-up visits. DMEK only replaces the diseased central endothelium; however, it does not heal ICE syndrome or posterior polymorphous dystrophy. The pathological endothelial cells persist at the peripheral cornea after surgery. These cells may induce corneal decompensation in the future, although the graft border could be a mechanical barrier delaying migration from the periphery to the central cornea. Treatment of glaucoma in ICE syndrome may be challenging. Hohberger et al. presented a case with micro bypass Xen Gel stent after DMEK. They concluded that microinvasive surgery after DMEK has less adverse effects and provides good IOP regulation.

Conclusion

Data from the Eye Bank Association of America shows that between 2004 and 2014, the rate of PK decreased to half (from 95% to 42%) and was replaced by lamellar keratoplasty techniques (5% to 55%). The volume of EK procedures has been doubling every year since 2011. Fuchs endothelial dystrophy (47.7%) is the most common cause of endothelial failure, followed by corneal edema after cataract surgery (17.8%) that needs EK. DMEK offers significantly better graft survival of 98.7% in these eyes than DSAEK (78.4%) and PK (73.5%) in Fuchs endothelial dystrophy. PK results in eight-fold higher rejection rates compared to DMEK. For challenging cases like eyes with glaucoma, failed grafts, and vitrectomized eyes, DMEK still offers quick visual recovery, better graft survival, and lower rejection rates compared to traditional PK.

Although it has a learning curve, the literature on new techniques of DMEK is expanding tremendously, making it possible to perform DMEK in a variety of challenging situations.
This review summarized different approaches such as using different graft sizes (hemi-DMEK, quarter-DMEK), different graft folding techniques (endothelium-in delivery methods), new unfolding techniques (using a diaphragm in vitrectomized eyes), new positioning techniques (3/4-DMEK in eyes with glaucoma shunts), and double layers of DM in cases of failed PK. Hopefully, more standardized innovative modifications will enable cornea surgeons to treat endothelial dysfunction in almost any situation with confidence and great success.

**Peer-review:** Internally peer reviewed.

**Authorship Contributions**

Surgical and Medical Practices: Ö.È.K., G.M., Concept: Ö.È.K., E.E.K., S.O., G.M., Design: Ö.È.K., E.E.K., G.M., Data Collection or Processing: Ö.È.K., E.E.K., Analysis or Interpretation: S.O., G.M., Literature Search: Ö.È.K., E.E.K., Writing: Ö.È.K., E.E.K.

**Conflict of Interest:** No conflict of interest was declared by the authors.

**Financial Disclosure:** The authors declared that this study received no financial support.

**References**

1. Melles GR. Posterior lamellar keratoplasty: DLEK to DSEK to DMEK. Cornea. 2006;25:879-881.
2. Dapena I, Ham L, Melles GR. Endothelial keratoplasty: DSEK/DSPAEK or DMEK—the thinner the better? Curr Opin Ophthalmol. 2009;20:299-307.
3. Melles GR, Ong TS, Ververs B, van der Wees J. Preliminary clinical results of Descemet membrane endothelial keratoplasty. Am J Ophthalmol. 2008;145:222-227.
4. Price MO, Fairchild KM, Price DA, Price FW Jr. Descemet's stripping endothelial keratoplasty five-year graft survival and endothelial cell loss. Ophthalmology. 2011;118:725-729.
5. Woo JH, Ang M, Hoon HM, Tan D. Descemet Membrane Endothelial Keratoplasty Versus Descemet Stripping Automated Endothelial Keratoplasty and Penetrating Keratoplasty. Am J Ophthalmol. 2019;207:288-303.
6. Lee WB, Jacobs DS, Munch DC, Kaufman SC, Reinhart WJ, Shtriem RM. Descemet's stripping endothelial keratoplasty: safety and outcomes: a report by the American Academy of Ophthalmology. Ophthalmology. 2009;116:1818-1830.
7. Singh NP, Said DG, Dua HS. Lamellar keratoplasty techniques. Indian J Ophthalmol. 2018;66:1239-1250.
8. Terry MA. Endothelial keratoplasty: why aren't we all doing Descemet membrane endothelial keratoplasty? Cornea. 2012;31:469-471.
9. Deng SX, Lee WB, Hammersmith KM, Kuo AN, Li JY, Shen JF, Westert MP, Shein RM. Descemet Membrane Endothelial Keratoplasty: Safety and Outcomes: A Report by the American Academy of Ophthalmology. Ophthalmology. 2018;125:295-310.
10. Birbal RS, Ni Dhubhghaill S, Bourgonje VJA, Hanko J, Ham L, Bourgonje VJA, Dapena I, Oellerich S, Melles GRJ. Quarter-Descemet Membrane Endothelial Keratoplasty in Postvitrectomy Eyes With the Use of Pars Plana Infusion. Cornea. 2017;36:280-285.
11. Moshirfar M, Horner C, Bourgonje VJA, Dapena I, Oellerich S, Melles GRJ. Quarter-Quarter-Quarter-Quarter-Quarter Descemet Membrane Endothelial Keratoplasty (hemi-DMEK). Br J Ophthalmol. 2016;100:420-424.

12. Vajpayee RB, Sharma N, Jhanvi V, Tityal JS, Tandon R. One donor cornea for 3 recipients: a new concept for cornea transplantation surgery. Arch Ophthalmol. 2007;125:552-554.
13. Gain P, Julienne R, Ho Z, Aldossary M, Acquart S, Cognasse F, Thuret G. Global Survey of Corneal Transplantation and Eye Banking. JAMA Ophthalmol. 2016;134:167-173.
14. Lam FC, Baydoun L, Dirisamer M, Lie J, Dapena I, Melles GR. Hemi-Descemet membrane endothelial keratoplasty transplantation: a potential method for increasing the pool of endothelial graft tissue. JAMA Ophthalmol. 2014;132:1469-1473.
15. Lie JT, Lam FC, Groeneveld-van Beek EA, van der Wees J, Melles GR. Graft preparation for hemi-Descemet membrane endothelial keratoplasty (hemi-DMEK). Br J Ophthalmol. 2016;100:420-424.
16. Van den Bogerd B, Dhubhghaill SN, Koppen C, Tassignon MJ, Zakaria N. A review of the evidence for in vivo corneal endothelial regeneration. Surv Ophthalmol. 2018;63:149-165.
17. Müller TM, Baydoun L, Melles GR. 3-Year update on the first case series of hemi-Descemet membrane endothelial keratoplasty. Graefes Arch Clin Exp Ophthalmol. 2017;255:213-215.
18. Lam FC, Baydoun L, Satue M, Dirisamer M, Ham L, Melles GR. One year outcome of hemi-Descemet membrane endothelial keratoplasty. Graefes Arch Clin Exp Ophthalmol. 2015;253:1955-1958.
19. Zygoura V, Baydoun L, Ham L, Bourgonje VJA, van Dijk K, Lie JT, Dapena I, Oellerich S, Melles GRJ. Quarter-Descemet Membrane endothelial keratoplasty (Quarter-DMEK) for Fuchs endothelial corneal dystrophy: 6 months clinical outcome. Br J Ophthalmol. 2018;102:1425-1430.
20. Birbal RS, Ni Dhubhghaill S, Baydoun L, Ham L, Bourgonje VJA, Dapena I, Oellerich S, Melles GRJ. Quarter-Quarter-Quarter-Quarter-Quarter Descemet Membrane Endothelial Keratoplasty With a Pull-Through Insertion Device: Surgical Technique, Endothelial Cell Loss, and Early Clinical Results. Cornea. 2020;39:558-565.
21. Terry MA, Sraiko MD, Veldman PB, Talajic JC, VanZel C, Sales CS, Mayko ZM. Standardized DMEK Technique: Reducing Complications Using Prestrippled Tissue, Novel Glass Injector, and Sulfor Hexafluoride (SF6) Gas. Cornea. 2015;34:845-852.
22. Birbal RS, Ni Dhubhghaill S, Baydoun L, Ham L, Bourgonje VJA, Dapena I, Oellerich S, Melles GRJ. Quarter-Quarter-Quarter-Quarter-Quarter Descemet Membrane Endothelial Keratoplasty: One- to Two-Year Clinical Outcomes. Cornea. 2020;39:277-282.
23. Oganesyan OG, Nereov VV, Gruikanjan AA, Getadaryan VR. Five Keratoplasties From One Donor Cornea. Cornea. 2018;37:667-671.
24. Tan TE, Devarajan K, Seah XY, Lai SJ, Peh GSL, Cajucom-Uy HY, Ang M, Mehta JS, Tan DTH. Descemet Membrane Endothelial Keratoplasty With a Pull-Through Insertion Device: Surgical Technique, Endothelial Cell Loss, and Early Clinical Results. Cornea. 2020;39:558-565.
25. Terry MA, Sraiko MD, Veldman PB, Talajic JC, VanZel C, Sales CS, Mayko ZM. Standardized DMEK Technique: Reducing Complications Using Prestrippled Tissue, Novel Glass Injector, and Sulfor Hexafluoride (SF6) Gas. Cornea. 2015;34:845-852.
26. Birbal RS, Hoon HM, Tan D. Hybrid Descemet Membrane Endothelial Keratoplasty (H-DMEK): results of a donor insertion pull-through technique using donor stroma as carrier. Br J Ophthalmol. 2020;104:1358-1362.
27. Serkin N, Einan-Lifshitz A, Ashkenazy Z, Boutin T, Shoval M, Borovik A, Alorbhami M, Chan CC, Rootman DS. Enhancing Descemet Membrane Endothelial Keratoplasty in Postvitrectomy Eyes With the Use of Pars Plana Infusion. Cornea. 2017;36:280-285.
28. Mednick Z, Serkin N, Einan-Lifshitz A, Santealla G, Trinh T, Chan CC, Rootman DS. Long-Term Outcomes of Descemet Membrane Endothelial Keratoplasty in Postvitrectomized Eyes With the Use of Pars Plana Infusion. Cornea. 2020;39:457-460.
29. Yoeruek E, Rubino G, Bayyoud T, Barz-Schmidt KU. Descemet membrane endothelial keratoplasty in vitrectomized eyes: clinical results. Cornea. 2015;34:1-5.
30. Spaniol K, Holmram C, Schwinde JH, Deffia S, Guthoff R, Geerling G. Descemet-membrane endothelial keratoplasty in patients with retinal commorbidities-a prospective cohort study. Inn J Ophthalmol. 2016;9:390-394.
31. Benneet A, Mahmoud S, Drury D, Cavanaugh HD, McCalley JP, Pettrol WM, Moreha VV. Impact of Donor Age on Corneal Endothelium-Descemet Membrane Layer Scroll Formation. Eye Contact Lens. 2015;41:236-239.
32. Yoeruek E, Bayyoud T, Hofmann J, Barz-Schmidt KU. Novel maneuver facilitating Descemet membrane unfolding in the anterior chamber. Cornea. 2013;32:370-373.
33. Veldman PB, Dye PK, Holiman JD, Mayko ZM, Sales CS, Sraiko MD, Stoeger CG, Terry MA. Stamping an S on DMEK Donor Tissue to
Prevent Upside-Down Grafts: Laboratory Validation and Detailed Preparation Technique Description. Cornea. 2015;34:1175-1178.

34. Liarakos VS, Dapena I, Ham L, van Dijk K, Melles GR. Intracorneal graft unfolding techniques in descemet membrane endothelial keratoplasty. JAMA Ophthalmol. 2013;131:29-35.

35. Izbizky G, Meller C, Grasso M, Velazco A, Penalta O, Otano L, Garcia-Monaco R. Feasibility and safety of prophylactic uterine artery catheterization and embolization in the management of placenta accreta. J Vasc Interv Radiol. 2015;26:162-169; quiz 170.

36. Hayashi T, Kobayashi A. Double-Bubble Technique in Descemet Membrane Endothelial Keratoplasty for Vitrectomized Eyes: A Case Series. Cornea. 2018;37:1185-1188.

37. Droskas K, Bertelmann T, Schneider FM, Papapantostinos D, Sekundo W. A simple rescue maneuver for unfolding and centering a tightly rolled graft in Descemet membrane endothelial keratoplasty. Clin Ophthalmol. 2014;8:2161-2163.

38. Yoertuk E, Bartz-Schmidt KU. Novel Technique for Improving Graft Unfolding in Vitrectomized Eyes Using a Temporary Diaphragm in Descemet Membrane Endothelial Keratoplasty. Cornea. 2018;37:1334-1336.

39. Karadag R, Akyurt V, Esen F, Oguz H, Demirok A. Descemet’s membrane endothelial keratoplasty in aphakic and vitrectomized eye. GMS Ophthalmol Cases. 2020;10:Doc02.

40. Saad A, Awad SL, El-Salloukh NA, Panthier C, Buhur Z, Gatinel D. C-Press Technique to Facilitate Descemet Membrane Endothelial Keratoplasty Surgery in Vitrectomized Patients: A Case Series. Cornea. 2019;38:1198-1201.

41. Schirrenlocher S, Schleer SL, Siebelmann S, Hayashi T, Mathaeri M, Bachmann B, Cursiefen C. Long-term outcome of descemet membrane endothelial keratoplasty (DMEK) following failed penetrating keratoplasty (PK). Acta Ophthalmol. 2020;98:e901-e906.

42. Pasari A, Price MO, Feng MT, Price FW Jr. Descemet Membrane Endothelial Keratoplasty for Failed Penetrating Keratoplasty: Visual Outcomes and Graft Survival. Cornea. 2019;38:151-156.

43. Price FW Jr., Price MO. Endothelial keratoplasty to restore clarity to a failed penetrating graft. Cornea. 2006;25:895-899.

44. Price FW Jr., Price MO, Arudndhi A. Descemet stripping automated endothelial keratoplasty under failed penetrating keratoplasty: how to avoid complications. Am J Ophthalmol. 2011;151:187-188 e182.

45. Anshu A, Price MO, Price FW Jr. Descemet membrane endothelial keratoplasty and hybrid techniques for managing failed penetrating grafts. Cornea. 2013;32:1-4.

46. Levy I, Liarakos VS, Verdijk RM, Parker J, Muller TM, Bruinsma M, Binder PS, Melles GRJ. Outcome and Histopathology of Secondary Penetrating Keratoplasty Graft Failure Managed by Descemet Membrane Endothelial Keratoplasty. Cornea. 2017;36:777-781.

47. Gundlach E, Maier AK, Riechardt AI, Brockmann T, Bertelmann E, Jousen A, Torun N. Descemet Membrane Endothelial Keratoplasty as a Secondary Approach After Failure of Penetrating Keratoplasty. Exp Clin Transplant. 2015;13:350-354.

48. Heinzelmuller S, Borngreter D, Eberspacher P, Lapp T, Reinhardt T, Mair P. Descemet membrane endothelial keratoplasty for graft failure following penetrating keratoplasty. Graefes Arch Clin Exp Ophthalmol. 2017;255:979-985.

49. Keane MC, Galetis RA, Mills RA, Coster DJ, Williams KA, for Contributors to the Australian Corneal Graft R. A comparison of endothelial and penetrating keratoplasty outcomes following failed penetrating keratoplasty: a registry study. Br J Ophthalmol. 2016;100:1569-1575.

50. Park CY, Chuck RS. Non-Descemet stripping Descemet membrane endothelial keratoplasty. Cornea. 2013;32:1607-1609.

51. Allo Del Barrio JL, Montesel A, Ho V, Bhagal M. Descemet Membrane Endothelial Keratoplasty Under Failed Penetrating Keratoplasty Without Host Descemetorhexis for the Management of Secondary Graft Failure. Cornea. 2020;39:13-17.

52. Pilger D, von Sonnleithner C, Bertelmann E, Jousen AM, Torun N. Femtosecond Laser-Assisted Descemetorhexis: A Novel Technique in Descemet Membrane Endothelial Keratoplasty. Cornea. 2016;35:1274-1278.

53. Sella R, Einan-Lifshitz A, Sorkin N, Chan CC, Afshari NA, Rootman DS. Learning curve of two common Descemet membrane endothelial keratoplasty graft preparation techniques. Can J Ophthalmol. 2019;54:467-472.

54. Sorkin N, Trinh T, Einan-Lifshitz A, Mednick Z, Santeilla G, Telli A, Belkin A, Chan CC, Rootman DS. Outcomes of femtosecond laser-assisted Descemet membrane endothelial keratoplasty for failed penetrating keratoplasty. Can J Ophthalmol. 2019;54:741-745.

55. Einan-Lifshitz A, Belkin A, Sorkin N, Mednick Z, Boutin T, Gill I, Karimi M, Chan CC, Rootman DS. Descemet Membrane Endothelial Keratoplasty After Penetrating Keratoplasty: Features for Success. Cornea. 2018;37:1093-1097.

56. Einan-Lifshitz A, Sorkin N, Boutin T, Showall M, Bonovik A, Aloddhani M, Chan CC, Rootman DS. Comparison of Femtosecond Laser-Enabled Descemeterhexis and Manual Descemeterhexis in Descemet Membrane Endothelial Keratoplasty. Cornea. 2017;36:767-770.

57. Azarvain J, Yu F, Deng SX. Outcomes of Descemet Membrane Endothelial Keratoplasty in Patients With Previous Glaucoma Surgery. Cornea. 2017;36:284-289.

58. Rosenfeld C, Price MO, Lai X, Witzmann FA, Price FW Jr. Distinctive and pervasive alterations in aqueous humor protein composition following different types of glaucoma surgery. Mol Vis. 2015;21:911-918.

59. Birbal RS, Tong CM, Dapena I, Parker JS, Parker JS, Oellerich S, Melles GRJ. Clinical Outcomes of Descemet Membrane Endothelial Keratoplasty in Eyes With a Glaucoma Drainage Device. Am J Ophthalmol. 2019;199:150-158.

60. Sorkin N, Mirmoumi M, Kisilevsky E, Boutin T, Cohen E, Trinh T, Santeilla G, Slomovic AR, Chan CC, Rootman DS. Four-Year Survival of Descemet Membrane Endothelial Keratoplasty in Patients With Previous Glaucoma Surgery. Am J Ophthalmol. 2020;218:7-16.

61. Lin SB, Prapuipanch P, Yu F, Law SK, Caprioli J, Aaldave AJ, Deng SX. Comparison of Endothelial Keratoplasty Techniques in Patients With Prior Glaucoma Surgery: A Case-Matched Study. Am J Ophthalmol. 2019;206:94-101.

62. Topouzis F, Coleman AL, Choiplin N, Bernard MM, Hill R, Yu F, Panek WC, Wilson MR. Follow-up of the original cohort with the Ahmed glaucoma valve implant. Am J Ophthalmol. 1999;128:198-204.

63. Anshu A, Price MO, Richardson MR, Segu ZM, Lai X, Yoder MC, Price FW Jr. Alterations in the aqueous humor proteome in patients with a glaucoma shunt device. Mol Vis. 2011;17:1891-1900.

64. Oganessian O, Makarov P, Grekianany A, Oganessian C, Getadayan V, Melles GRJ. Three-quarter DMEK in eyes with glaucoma draining devices to avoid secondary graft failure. Acta Ophthalmol. 2021;99:569-574.

65. Ni N, Sperling BJ, Dai Y, Hannush SB. Outcomes After Descemet Stripping Automated Endothelial Keratoplasty in Patients With Glaucoma Drainage Devices. Cornea. 2015;34:870-875.

66. van Dijk K, Rodriguez-Calvo-de-Mora M, van Esch H, Frank L, Dapena I, Baydoun L, Oellerich S, Melles GR. Two-Year Refractive Outcomes After Descemet Membrane Endothelial Keratoplasty. Cornea. 2016;35:1548-1555.

67. Rock T, Bartz-Schmidt KU, Rock D, Yonenek E. Refractive changes after Descemet membrane endothelial keratoplasty. Ophthalmologe. 2014;111:649-653.

68. Alnaawasheh M, Rosenthaler A, Eter N, Zumhagen L. Changes in Corneal Refractive Power for Patients With Fuchs Endothelial Dystrophy After DMEK. Cornea. 2016;35:1073-1077.

69. Ham L, Dapena I, Moutsouris K, Balchandran C, Frank LE, van Dijk K, Melles GR. Refractive change and stability after Descemet membrane endothelial keratoplasty. Effect of corneal dehydration-induced hyperopic shift on intraocular lens power calculation. J Cataract Refract Surg. 2011;37:1455-1464.

70. Chaurasia S, Price FW Jr., Gundersen L, Price MO. Descemet’s membrane endothelial keratoplasty: clinical results of single versus triple procedures (combined with cataract surgery). Ophthalmology. 2014;121:454-458.

71. Laster K, Bachmann BO, Horn FK, Curfee C, Kruse FE. Descemet membrane endothelial keratoplasty combined with phacoemulsification and intraocular lens implantation: advanced triple procedure. Am J Ophthalmol. 2012;154:47-55 e42.
72. Gundlach E, Maier AK, Tsangaridou MA, Riechardt AI, Bruckmann T, Bertelmann E, Joussen AM, Torun N. DMEK in phakic eyes: targeted therapy or highway to cataract surgery? Graefes Arch Clin Exp Ophthalmol. 2015;253:909-914.
73. Schoenberg ED, Price FW, Jr., Miller J, McKee Y, Price MO. Refractive outcomes of Descemet membrane endothelial keratoplasty triple procedures (combined with cataract surgery). J Cataract Refract Surg. 2015;41:1182-1189.
74. Arslan OS, Dogan C, Mergen B. Six-Month Results of Descemet Membrane Endothelial Keratoplasty in 100 Eyes: First Clinical Results from Turkey. Turk J Ophthalmol. 2019;49:235-242.
75. Augustin VA, Weller JM, Kruse FE, Tourtas T. Refractive Outcomes After Descemet Membrane Endothelial Keratoplasty + Cataract/Intraocular Lens Triple Procedure: A Fellow Eye Comparison. Cornea. 2021;40:883-887.
76. Yokogawa H, Sanchez PJ, Mayko ZM, Szaiko MD, Terry MA. Astigmatism Correction With Toric Intraocular Lenses in Descemet Membrane Endothelial Keratoplasty Triple Procedures. Cornea. 2017;36:269-274.
77. Parker J, Drisamer M, Naveiras M, Tse WH, van Dijk K, Frank LE, Ham L, Melles GR. Outcomes of Descemet membrane endothelial keratoplasty in phakic eyes. J Cataract Refract Surg. 2012;38:871-877.
78. Bayshous L, van Dijk K, Dapena I, Musa FU, Liarakos VS, Ham L, Melles GR. Repeat Descemet membrane endothelial keratoplasty after complicated primary Descemet membrane endothelial keratoplasty. Ophthalmology. 2015;122:8-16.
79. Musa FU, Cabrero J, Quilendrino R, Dapena I, Ham L, Melles GR. Outcomes of phacoemulsification after Descemet membrane endothelial keratoplasty. J Cataract Refract Surg. 2015;39:836-840.
80. Dapena I, Yeh RY, Quilendrino R, Melles G. Surgical step to facilitate phacoemulsification after Descemet membrane endothelial keratoplasty. J Cataract Refract Surg. 2012;38:1106-1107.
81. Bachmann B, Schrittenlocher S, Matthaei M, Siebelmann S, Cursiefen C. [Descemet membrane endothelial keratoplasty in complex eyes]. Ophthalmologe. 2019;116:228-235.
82. Weller JM, Tourtas T, Kruse FE. Feasibility and Outcome of Descemet Membrane Endothelial Keratoplasty in Complex Anterior Segment and Vitreous Disease. Cornea. 2015;34:1351-1357.
83. Sorkin N, Einan-Lifshitz A, Bourtin T, Showal M, Borovik A, Chan CC, Rootman DS. Descemet membrane endothelial keratoplasty in iridocorneal endothelial syndrome and posterior polymorphous corneal dystrophy. Can J Ophthalmol. 2019;54:190-195.
84. Hohberger B, Welge-Luehn UC, Lammer R. ICE-Syndrome: A Case Report of Implantation of a Microbypass Xen Gel Stent After DMEK Transplantation. J Glaucoma. 2017;26:e103-e104.
85. Park CY, Lee JK, Gore PK, Lim CY, Chuck RS. Keratoplasty in the United States: A 10-Year Review from 2005 through 2014. Ophthalmology. 2015;122:2432-2442.